CureVac Advances Seasonal Flu Study To Phase 2 In Collaboration With GSK Following Selection Of Promising mRNA Vaccine Candidate With Broad Coverage, The Trial Is Expected To Start Dosing In Q4 2023
Portfolio Pulse from Benzinga Newsdesk
CureVac is advancing its seasonal flu study to Phase 2 in collaboration with GSK. The trial, which is based on a promising mRNA vaccine candidate with broad coverage, is expected to start dosing in Q4 2023.
September 12, 2023 | 11:20 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CureVac's advancement to Phase 2 of its seasonal flu study in collaboration with GSK could potentially boost its stock in the short term.
The advancement of CureVac's seasonal flu study to Phase 2 indicates progress in its research and development efforts. This could potentially attract more investors, leading to a rise in its stock price.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
GSK's collaboration with CureVac on the advancement of the seasonal flu study to Phase 2 could potentially have a positive impact on its stock.
GSK's collaboration with CureVac on the seasonal flu study indicates its active involvement in research and development. This could potentially attract more investors, leading to a rise in its stock price.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 80